Morgan Stanley Chroma Dex Corp. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Chroma Dex Corp. stock. As of the latest transaction made, Morgan Stanley holds 606,718 shares of CDXC stock, worth $3.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

606,718

Previous 264,945 129.0%

Holding current value

$3.73 Million

Previous $1.83 Million 103.77%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$5.42 - $7.08 $1.85 Million - $2.42 Million	341,773 Added 129.0%	606,718 $3.73 Million
Q1 2025 May 15, 2025	BUY	$5.26 - $8.55 $578,973 - $941,107	110,071 Added 71.07%	264,945 $1.83 Million
Q4 2024 Feb 14, 2025	SELL	$3.25 - $7.72 $28,447 - $67,573	-8,753 Reduced 5.35%	154,874 $822,000
Q3 2024 May 14, 2025	BUY	$2.51 - $3.8 $235,638 - $356,744	93,880 Added 134.6%	163,627 $597,000
Q3 2024 Nov 14, 2024	BUY	$2.51 - $3.8 $235,638 - $356,744	93,880 Added 134.6%	163,627 $597,000
Q2 2024 May 14, 2025	SELL	$2.44 - $4.32 $207,709 - $367,748	-85,127 Reduced 54.97%	69,747 $190,000
Q2 2024 Oct 17, 2024	BUY	$2.44 - $4.32 $60,978 - $107,961	24,991 Added 55.84%	69,747 $190,000
Q2 2024 Aug 14, 2024	BUY	$2.44 - $4.32 $60,978 - $107,961	24,991 Added 55.84%	69,747 $190,000
Q1 2024 Oct 17, 2024	SELL	$1.36 - $3.84 $33,987 - $95,965	-24,991 Reduced 35.83%	44,756 $155,000
Q1 2024 Aug 16, 2024	BUY	$1.36 - $3.84 $52,043 - $146,945	38,267 Added 589.72%	44,756 $155,000
Q1 2024 May 15, 2024	BUY	$1.36 - $3.84 $52,043 - $146,945	38,267 Added 589.72%	44,756 $155,000
Q4 2023 Aug 16, 2024	SELL	$1.28 - $1.6 $80,970 - $101,212	-63,258 Reduced 90.7%	6,489 $9,000
Q4 2023 Feb 13, 2024	BUY	$1.28 - $1.6 $367 - $459	287 Added 4.63%	6,489 $9,000
Q3 2023 Nov 15, 2023	SELL	$1.36 - $1.77 $3,088 - $4,019	-2,271 Reduced 26.8%	6,202 $9,000
Q2 2023 Aug 14, 2023	SELL	$1.31 - $1.79 $2,038 - $2,785	-1,556 Reduced 15.52%	8,473 $13,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.19 $6,907 - $10,220	-4,667 Reduced 31.76%	10,029 $15,000
Q4 2022 Feb 14, 2023	SELL	$1.25 - $1.94 $13,393 - $20,787	-10,715 Reduced 42.17%	14,696 $24,000
Q3 2022 Nov 14, 2022	SELL	$1.19 - $2.06 $154,546 - $267,534	-129,871 Reduced 83.64%	25,411 $31,000
Q2 2022 Oct 27, 2022	BUY	$1.59 - $2.7 $115,435 - $196,022	72,601 Added 87.81%	155,282 $259,000
Q2 2022 Aug 15, 2022	BUY	$1.59 - $2.7 $115,435 - $196,022	72,601 Added 87.81%	155,282 $259,000
Q1 2022 Oct 27, 2022	SELL	$2.02 - $3.92 $146,654 - $284,595	-72,601 Reduced 46.75%	82,681 $203,000
Q1 2022 May 13, 2022	SELL	$2.02 - $3.92 $5,363 - $10,407	-2,655 Reduced 3.11%	82,681 $203,000
Q4 2021 Feb 14, 2022	SELL	$3.74 - $6.7 $54,110 - $96,935	-14,468 Reduced 14.5%	85,336 $319,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $10.41 $603,814 - $1.04 Million	99,804 New	99,804 $626,000

Others Institutions Holding CDXC

# of Institutions

167

Shares Held

27.9M

Call Options Held

152K

Put Options Held

178K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $420M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account